Media headlines about Rosetta Genomics (NASDAQ:ROSG) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rosetta Genomics earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 45.235212590122 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, Barrington Research downgraded Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.
Shares of Rosetta Genomics (NASDAQ ROSG) remained flat at $$0.58 during mid-day trading on Wednesday. The company had a trading volume of 87,800 shares, compared to its average volume of 108,480. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 0.03. Rosetta Genomics has a 1-year low of $0.48 and a 1-year high of $6.84.
TRADEMARK VIOLATION WARNING: This piece of content was posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-rosetta-genomics-rosg-share-price/1823026.html.
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH).
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.